Get the Stockscreener App
12.34
7.40%
0.85
Atara Biotherapeutics Inc stock is traded at $12.34, with a volume of 90,718.
It is up +7.40% in the last 24 hours and down -5.22% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
See More
Previous Close:
$11.49
Open:
$11.72
24h Volume:
90,718
Relative Volume:
1.61
Market Cap:
$86.66M
Revenue:
$100.44M
Net Income/Loss:
$-133.16M
P/E Ratio:
-0.479
EPS:
-25.76
Net Cash Flow:
$-94.85M
1W Performance:
+0.41%
1M Performance:
-5.22%
6M Performance:
+73.56%
1Y Performance:
+73.31%
1-Day Range:
$11.62
$12.40
1-Week Range:
$11.20
$12.50
52-Week Range:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4211
Address
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
12.34 | 80.62M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-09-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
| Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Downgrade | Citigroup | Buy → Neutral |
| May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Initiated | Evercore ISI | Outperform |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
| Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
| Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| May-23-19 | Initiated | Stifel | Buy |
| Jan-23-19 | Initiated | Mizuho | Buy |
| Apr-10-18 | Initiated | JP Morgan | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Mar-05-18 | Reiterated | Jefferies | Buy |
| Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
| Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
Atara Biotherapeutics Inc. Stock Recovery Path — Analyst Breakdown2025 Big Picture & Real-Time Chart Pattern Alerts - newsyoung.net
Atara biotherapeutics (ATRA) director Huang buys $670k in stock - Investing.com
Mizuho lowers Atara Biotherapeutics stock price target on delayed tab-cel launch By Investing.com - Investing.com South Africa
Published on: 2025-08-19 07:43:26 - beatles.ru
Atara Biotherapeutics Maintains $16 Price Target After Mizuho Securities Reaffirms Buy Rating - AInvest
Atara Makes Second Try With FDA - Los Angeles Business Journal
Atara Biotherapeutics shares rise 2.61% after-hours following Mizuho's price target cut to $16. - AInvest
Mizuho lowers Atara Biotherapeutics stock price target on delayed tab-cel launch - Investing.com
What’s next for Atara Biotherapeutics Inc. stock priceJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - Newser
Understanding Atara Biotherapeutics Inc.’s price movementChart Signals & AI Enhanced Trading Signals - Newser
Measuring Atara Biotherapeutics Inc.’s beta against major indicesJuly 2025 Drop Watch & Accurate Intraday Trading Signals - Newser
Atara Biotherapeutics Inc. Rebound Backed by Sentiment ShiftPortfolio Performance Summary & Short-Term High Return Strategies - newsyoung.net
Risk vs reward if holding onto Atara Biotherapeutics Inc.2025 Trading Volume Trends & Weekly High Return Stock Opportunities - Newser
Elliott Wave Theory Predicts Pullback in Atara Biotherapeutics Inc.Portfolio Gains Report & Low Risk High Reward Trade Ideas - sundaytimes.kr
How high can Atara Biotherapeutics Inc. stock goTrade Risk Assessment & High Win Rate Trade Alerts - Newser
Atara Biotherapeutics Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Why Atara Biotherapeutics Inc. is moving todayQuarterly Trade Report & Proven Capital Preservation Methods - Newser
Multi asset correlation models including Atara Biotherapeutics Inc.2025 Market Sentiment & Reliable Price Action Trade Plans - Newser
Atara Biotherapeutics Inc. stock daily chart insightsMarket Volume Report & Low Drawdown Momentum Trade Ideas - Newser
How to interpret RSI for Atara Biotherapeutics Inc. stockQuarterly Investment Review & Safe Entry Momentum Tips - Newser
Drawdown in Atara Biotherapeutics Inc. May Be Nearing EndGold Moves & Daily Momentum Trading Reports - beatles.ru
What does recent volatility data suggest for Atara Biotherapeutics Inc.Trade Entry Summary & Verified Short-Term Plans - Newser
Using Python tools to backtest Atara Biotherapeutics Inc. strategiesJuly 2025 Setups & Consistent Growth Equity Picks - Newser
There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues Despite A 25% Share Price Rise - simplywall.st
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 25% Though Its Price And Business Still Lag The Industry - 富途牛牛
Will Atara Biotherapeutics Inc. bounce back from current supportIPO Watch & Accurate Technical Buy Alerts - Newser
Risk adjusted return profile for Atara Biotherapeutics Inc. analyzedFree Early Entry Picks Before News Breakout - Newser
What makes Atara Biotherapeutics Inc. stock price move sharplyStrong ROI Equity Ideas - kangso.co.kr
Is Atara Biotherapeutics Inc. building a consolidation baseDaily Investment Ideas with Market Insight - Newser
Atara Biotherapeutics: Q2 Earnings Snapshot - Norwalk Hour
Technical signs of recovery in Atara Biotherapeutics Inc.Trend Confirmation Scanner with Entry Focus - Newser
How Atara Biotherapeutics Inc. stock performs during market volatilityConsistent Gain Plan with AI Support - Newser
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics shares rise 2.13% after-hours after FDA accepted BLA for tabelecleucel. - AInvest
Atara Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress | ATRA Stock News - GuruFocus
Atara Biotherapeutics Reports Q2 Financial Results, Resumes Strategic Options Evaluation - AInvest
Will Atara Biotherapeutics Inc. price bounce be sustainableCapital Safe Picks with Consistent Gains - Newser
What MACD signals say about Atara Biotherapeutics Inc.High Return Idea With Technical Filter - Newser
Is Atara Biotherapeutics Inc. showing signs of accumulationBuy Strategy Tracker with Growth Indicators - Newser
Atara Biotherapeutics (ATRA) Projected to Post Quarterly Earnings on Monday - Defense World
Atara ATRA Q2 2025 Earnings Preview Upside Potential on Strategic Partnerships - AInvest
Atara Biotherapeutics Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Biotech with Heart: Atara’s Path to Hope for MS & Cancer - Tomorrow's World Today
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Is About To Turn The Corner - sg.finance.yahoo.com
What is Atara Biotherapeutics Inc. company’s growth strategyUnlock powerful portfolio management tools - Jammu Links News
Is Atara Biotherapeutics Inc. stock ready for a breakoutHigh Return Trade Roadmap with Setup Filters - Newser
What is the risk reward ratio of investing in Atara Biotherapeutics Inc. stockUnlock exclusive trading strategies for gains - Jammu Links News
What are analysts’ price targets for Atara Biotherapeutics Inc. in the next 12 monthsStrong return on investment - Jammu Links News
What are the latest earnings results for Atara Biotherapeutics Inc.Rapid wealth multiplication - Jammu Links News
Does Atara Biotherapeutics Inc. stock perform well during market downturnsHigh-yield trading alerts - Jammu Links News
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atara Biotherapeutics Inc Stock (ATRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grant-Huerta Yanina | Chief Accounting Officer |
Aug 18 '25 |
Sale |
11.61 |
1,809 |
21,009 |
35,258 |
| Panacea Innovation Ltd | 10% Owner |
Aug 15 '25 |
Buy |
12.19 |
55,000 |
670,422 |
1,405,000 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):